Annual Total Liabilities
$195.74 M
+$31.39 M+19.10%
December 31, 2023
Summary
- As of February 12, 2025, IOVA annual total liabilities is $195.74 million, with the most recent change of +$31.39 million (+19.10%) on December 31, 2023.
- During the last 3 years, IOVA annual total liabilities has risen by +$83.78 million (+74.83%).
- IOVA annual total liabilities is now at all-time high.
Performance
IOVA Total Liabilities Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Quarterly Total Liabilities
$217.66 M
+$21.88 M+11.17%
September 30, 2024
Summary
- As of February 12, 2025, IOVA quarterly total liabilities is $217.66 million, with the most recent change of +$21.88 million (+11.17%) on September 30, 2024.
- Over the past year, IOVA quarterly total liabilities has increased by +$27.85 million (+14.67%).
- IOVA quarterly total liabilities is now at all-time high.
Performance
IOVA Quarterly Total Liabilities Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Total Liabilities Formula
Total Liabilities = Current Liabilities + Long-Term Liabilities
IOVA Total Liabilities Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly |
|---|---|---|
| 1 y1 year | +19.1% | +14.7% |
| 3 y3 years | +74.8% | +57.5% |
| 5 y5 years | +1238.1% | +57.5% |
IOVA Total Liabilities Highs & Lows
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | |
|---|---|---|---|---|---|
| 3 y | 3-year | at high | +25.7% | at high | +57.5% |
| 5 y | 5-year | at high | +328.5% | at high | +383.9% |
| alltime | all time | at high | >+9999.0% | at high | >+9999.0% |
Iovance Biotherapeutics Total Liabilities History
| Date | Annual | Quarterly |
|---|---|---|
| Sep 2024 | - | $217.66 M(+11.2%) |
| Jun 2024 | - | $195.78 M(+3.1%) |
| Mar 2024 | - | $189.81 M(-3.0%) |
| Dec 2023 | $195.74 M(+19.1%) | $195.74 M(+9.8%) |
| Sep 2023 | - | $178.31 M(-0.2%) |
| Jun 2023 | - | $178.72 M(+13.2%) |
| Mar 2023 | - | $157.89 M(-3.9%) |
| Dec 2022 | $164.34 M(+5.6%) | $164.34 M(+8.0%) |
| Sep 2022 | - | $152.19 M(+10.1%) |
| Jun 2022 | - | $138.19 M(-7.4%) |
| Mar 2022 | - | $149.26 M(-4.1%) |
| Dec 2021 | $155.67 M(+39.0%) | $155.67 M(+19.3%) |
| Sep 2021 | - | $130.50 M(+20.4%) |
| Jun 2021 | - | $108.38 M(+5.1%) |
| Mar 2021 | - | $103.14 M(-7.9%) |
| Dec 2020 | $111.96 M(+145.1%) | $111.96 M(+58.9%) |
| Sep 2020 | - | $70.45 M(+18.9%) |
| Jun 2020 | - | $59.26 M(+31.7%) |
| Mar 2020 | - | $44.98 M(-1.5%) |
| Dec 2019 | $45.68 M(+212.3%) | $45.68 M(+12.3%) |
| Sep 2019 | - | $40.68 M(+5.7%) |
| Jun 2019 | - | $38.50 M(+44.9%) |
| Mar 2019 | - | $26.57 M(+81.6%) |
| Dec 2018 | $14.63 M(+47.9%) | $14.63 M(-12.3%) |
| Sep 2018 | - | $16.67 M(+17.6%) |
| Jun 2018 | - | $14.18 M(-3.5%) |
| Mar 2018 | - | $14.69 M(+48.5%) |
| Dec 2017 | $9.89 M(+99.1%) | $9.89 M(+16.0%) |
| Sep 2017 | - | $8.53 M(-3.7%) |
| Jun 2017 | - | $8.86 M(+61.0%) |
| Mar 2017 | - | $5.50 M(+10.8%) |
| Dec 2016 | $4.97 M | $4.97 M(+55.5%) |
| Sep 2016 | - | $3.19 M(-30.7%) |
| Date | Annual | Quarterly |
|---|---|---|
| Jun 2016 | - | $4.61 M(+151.7%) |
| Mar 2016 | - | $1.83 M(+12.3%) |
| Dec 2015 | $1.63 M(-1.9%) | $1.63 M(-42.9%) |
| Sep 2015 | - | $2.85 M(+53.0%) |
| Jun 2015 | - | $1.87 M(-2.3%) |
| Mar 2015 | - | $1.91 M(+15.0%) |
| Dec 2014 | $1.66 M(-26.8%) | $1.66 M(+32.0%) |
| Sep 2014 | - | $1.26 M(+8.8%) |
| Jun 2014 | - | $1.16 M(-9.4%) |
| Mar 2014 | - | $1.28 M(-43.8%) |
| Dec 2013 | $2.27 M(-80.0%) | $2.27 M(-35.3%) |
| Sep 2013 | - | $3.51 M(+4.2%) |
| Jun 2013 | - | $3.37 M(-72.6%) |
| Mar 2013 | - | $12.31 M(+8.4%) |
| Dec 2012 | $11.35 M(-15.0%) | $11.35 M(-31.7%) |
| Sep 2012 | - | $16.61 M(-0.4%) |
| Jun 2012 | - | $16.68 M(-3.8%) |
| Mar 2012 | - | $17.34 M(+29.9%) |
| Dec 2011 | $13.35 M(+1522.2%) | $13.35 M(+46.2%) |
| Sep 2011 | - | $9.13 M(+388.2%) |
| Jun 2011 | - | $1.87 M(+142.5%) |
| Mar 2011 | - | $771.10 K(-6.3%) |
| Dec 2010 | $822.90 K(+3462.3%) | $822.90 K(+43.8%) |
| Sep 2010 | - | $572.20 K(+3521.5%) |
| Jun 2010 | - | $15.80 K(-55.1%) |
| Mar 2010 | - | $35.20 K(+52.4%) |
| Dec 2009 | $23.10 K(+600.0%) | $23.10 K(+69.9%) |
| Sep 2009 | - | $13.60 K(+23.6%) |
| Jun 2009 | - | $11.00 K(+32.5%) |
| Mar 2009 | - | $8300.00(+151.5%) |
| Dec 2008 | $3300.00 | $3300.00(+3.1%) |
| Sep 2008 | - | $3200.00(+60.0%) |
| Jun 2008 | - | $2000.00(+11.1%) |
| Mar 2008 | - | $1800.00 |
FAQ
- What is Iovance Biotherapeutics annual total liabilities?
- What is the all time high annual total liabilities for Iovance Biotherapeutics?
- What is Iovance Biotherapeutics annual total liabilities year-on-year change?
- What is Iovance Biotherapeutics quarterly total liabilities?
- What is the all time high quarterly total liabilities for Iovance Biotherapeutics?
- What is Iovance Biotherapeutics quarterly total liabilities year-on-year change?
What is Iovance Biotherapeutics annual total liabilities?
The current annual total liabilities of IOVA is $195.74 M
What is the all time high annual total liabilities for Iovance Biotherapeutics?
Iovance Biotherapeutics all-time high annual total liabilities is $195.74 M
What is Iovance Biotherapeutics annual total liabilities year-on-year change?
Over the past year, IOVA annual total liabilities has changed by +$31.39 M (+19.10%)
What is Iovance Biotherapeutics quarterly total liabilities?
The current quarterly total liabilities of IOVA is $217.66 M
What is the all time high quarterly total liabilities for Iovance Biotherapeutics?
Iovance Biotherapeutics all-time high quarterly total liabilities is $217.66 M
What is Iovance Biotherapeutics quarterly total liabilities year-on-year change?
Over the past year, IOVA quarterly total liabilities has changed by +$27.85 M (+14.67%)